NASDAQ OMX

Corline Biomedical AB: Datum för publicering av bokslutskommuniké

12.1.2017 13:59 | NASDAQ OMX

Dela

Corline Biomedical AB ("Corline") meddelar härmed att bokslutskommuniké för räkenskapsåret 2016 kommer att publiceras den 23 februari. Tidigare kommunicerat datum var den 25 februari.

I kvartalsrapporten för perioden 2016-07-01 - 2016-09-30 meddelades att Corlines bokslutskommuniké skulle publiceras den 25 februari. Rätt datum är den 23 februari.

Certified Adviser

Sedermera Fondkommission är Corlines Certified Adviser.

För mer information om Corline, vänligen kontakta

Henrik Nittmar, VD

Telefon: 018-71 30 90

E-post: henrik.nittmar@corline.se

Denna information är sådan information som Corline Biomedical AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning och lagen om värdepappersmarknaden. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande 2017-01-12

Corline Biomedical AB arbetar med den kroppsegna substansen heparin och har utvecklat en portfölj med läkemedelskandidater för användning i anslutning till organ- och celltransplantation. Bolaget planerar kliniska studier inom diabetes typ 1 och njurtransplantation, för vilket Corline även har erhållit särläkemedelsstatus ("Orphan Drug"). Inom ramen för helägda dotterbolaget Corline Pharma AB utvärderas in vivo-administration av Corlines heparinsubstans. 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Corline Biomedical AB via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste pressmeddelandena från NASDAQ OMX

ZIM Adds MatchBack Systems Analytics Services in Italy21.8.2017 22:00Pressmeddelande

Innovative approach to gain efficiencies through fewer empty container moves adds significant value for ZIM's customers GREEN BAY, Wis. and ROTTERDAM, The Netherlands, Aug. 21, 2017 (GLOBE NEWSWIRE) -- MatchBack Systems, Inc. ( www.matchbacksystems.com ), the leading software as a service (SaaS) solution to plan, optimize and automate matchbacks, announced that ZIM Integrated Shipping Ltd. joined the company's customer base on May 1, 2017 to optimize their inland operation in Italy. The account will be serviced through the European office in Rotterdam and corporate headquarters in North America. The system will be deployed for a 2 months pilot after which the parties will evaluate the scope for a broader cooperation. A photo accompanying this announcement is available at  http://www.globenewswire.com/NewsRoom/AttachmentNg/1cb9a632-22a4-4ff5-a3d5-d8b3964e5113 Gil Lehmann, Head of Global Land Tra

Promethean Opens New Global Headquarters in Seattle18.8.2017 18:38Pressmeddelande

Seattle, Wash., Aug. 18, 2017 (GLOBE NEWSWIRE) -- PrometheanTM, a global education technology company, announced today the opening of its new global headquarters in Seattle, Wash. Promethean's office in Atlanta, Ga. will continue to serve as the hub for the Americas markets, and the Blackburn, U.K. office will continue to carry on as the hub for the EMEA markets and parts of Asia.  Promethean is one of the leading brands in the international education technology market with more than 20 years of experience in the K-12 classroom. Its solutions are in more than 50,000 schools and institutions in 154 countries. "As traditional pedagogy continues to move towards immersive learning, it's important for Promethean to lead innovation in education with the latest technology," said Vin Riera, CEO of Promethean. "Seattle is a global technology hub, and establishing Promethean's global headquarters there increases opportunities for new business models, concepts

Hminers Disrupts the Cryptocurrency Market with Powerful, Multi-Algorithm Mining Rigs18.8.2017 11:00Pressmeddelande

Hminers continues to hit the headlines in the rapidly expanding global market for cryptocurrency. The Miami-based company has recently introduced three extremely powerful, multi-algorithm mining rigs that have been designed to provide maximum hash rate with minimum power consumption. MIAMI, Aug. 18, 2017 (GLOBE NEWSWIRE) -- In their relentless efforts to deliver state-of-the-art products related to cryptocurrency, Hminers has recently launched three brilliantly designed bitcoin mining rigs. The unique features and capabilities of the company's new H2U Miner, H4U Miner, and Rack Equipped with 5 x H4U have already grabbed the attention of the cryptocurrency enthusiasts and experts around the world. An organization with a rich tradition, Hminers (www.hminers.com) is recognized in the industry as the creator of the first ever 10 nm ASIC Chip in the world. Cryptocurrency mining is the process of generating new cryptocurrency that requires a pot

Nasdaq Welcomes I-AM Capital Acquisition Company (Nasdaq: IAMXU) to The Nasdaq Stock Market17.8.2017 18:50Pressmeddelande

NEW YORK, Aug. 17, 2017 (GLOBE NEWSWIRE) -- I-AM Capital Acquisition Company (Nasdaq:IAMXU), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, celebrated its initial public offering (IPO) on The Nasdaq Stock Market.  I-AM Capital's founders, Chief Executive Officer F. Jacob Cherian and Chief Financial Officer Suhel Kanuga, have been focused on investing into India over the last decade, with the distinction of completing the first listed-SPAC investment in India. "Through our keen focus and unique accomplishments in India over the last decade, we have seen our investment thesis bear fruit: India's prominence and rise on the world stage, its distinction as being one of the fastest growing major economies of the world, and its strong vibrant consumer demographics. We believe these factors are aligning well now,

Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency17.8.2017 14:30Pressmeddelande

WATERTOWN, Mass., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant (MDR) infections, today announced that the Marketing Authorization Application (MAA) for IV eravacycline for the treatment of complicated intra-abdominal infections (cIAI) has been submitted and was validated by the European Medicines Agency (EMA). Eravacycline is a novel, fully-synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. The MAA filing is based on data from the phase 3 IGNITE1 clinical trial in which eravacycline was well tolerated and demonstrated statistical non-inferiority to ertapenem using the primary endpoint of clinical response at the test-of-cure (TOC) visit. "The MAA filing represents a significant milestone for Tetraphase as it is our

RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules17.8.2017 13:00Pressmeddelande

RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories Esomeprazole Strontium DR Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI), indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions   RedHill expects to initiate the U.S. promotion of Esomeprazole Strontium  DR Capsules 49.3 mg  in the coming weeks   Esomeprazole Strontium  DR Capsules 49.3 mg  will be the third commercial GI product to be promoted by RedHill in the U.S.    RedHill's GI-focused sales force currently promotes two GI s

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum